Iron deficiency anaemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can impair quality of life. Guidelines recommend treatment to correct anaemia and replenish iron stores, either with oral iron products or with intravenous (IV) iron infusions where oral iron is ineffective, not tolerated or unsuitable. This study describes patterns of IDA treatment for IBD patients in five European countries. Responses were analysed from a structured online survey of 221 gastroenterologists from France, Germany, Italy, Spain and the UK who frequently treat IBD patients with IDA. Responses related to their three most recent such patients. Data were summarised descriptively. Data were collected on 654 patients (France 123, Germany 150, Italy 120, Spain 112, UK 149), of whom 55% were female. Mean age was 43 years (range 18-87), with 9% aged ≥65 years. Mean (SD) haemoglobin (Hb) level at baseline (i.e. at diagnosis of IDA) was 9.75(1.27)g/dL (range 4-14), mean serum ferritin was 113(98)μg/L, and mean iron need (Ganzoni formula) was 1,322(250)mg. After the most recent visit, in patients whose treatment was known (526/654 [80%]), 55% were treated with IV iron and 45% were on oral treatment. Ferric carboxymaltose (FCM) accounted for 78-91% of IV iron use depending on country. For the FCM course begun after the most recent visit (n=201), mean iron dose at first infusion was 748(362)mg; 132 patients (66%) had a second infusion, 33 (16%) had a third infusion and 17 (9%) a fourth. These data suggest that approximately half of gastroenterologist-treated IBD patients with IDA receive IV iron, with a majority receiving two or more infusions in a treatment course. As IV iron must be given at clinics with full resuscitation facilities, this will exert a burden in terms of healthcare resource use and patient inconvenience from travel and lost time.